Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Zydus Pharmaceuticals (USA) and Zynesher Pharmaceuticals have acquired the assets of K-V Pharmaceutical and its generic subsidiary Nesher Pharmaceuticals for $60m.
Subscribe to our email newsletter
The acquisition also covers K-V Pharma’s certain packaging, manufacturing and laboratory facilities including certain intellectual property, existing and future product opportunities, as well as equipment specific to the generic business.
Furthermore, K-V Pharma has signed a supply deal with Zydus Pharma to offer third-party manufacturing services for Gynazole-1 and Clindesse.
Nesher CEO Greg Divis said they will continue working towards making important progress with Makena, returning their branded anti-infective products back to market and supporting additional growth potential for Evamist.